---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-018203"
form_type: "8-K"
ticker: "VERA"
cik: "0001831828"
company_name: "Vera Therapeutics, Inc."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:45:56.543739+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vera Therapeutics announces positive per-protocol analysis from Phase 2b ORIGIN trial of atacicept in IgA nephropathy

## Summary
- At Week 24, atacicept 150 mg achieved 41% mean reduction in proteinuria and 34% delta vs placebo (p=0.025).
- At Week 36 interim, atacicept 150 mg showed 47% mean reduction from baseline and 48% delta vs placebo.
- Serious treatment-emergent AEs occurred in 2% of atacicept patients vs 9% in placebo; discontinuation rate 1%.
- Company plans to advance atacicept into pivotal Phase 3 in first half of 2023, after FDA discussions.
- Prespecified per-protocol analysis excluded 14 patients with protocol violations identified by blinded CRO.

## SEC filing metadata
- accession: 0001193125-23-018203
- form_type: 8-K
- ticker: VERA
- cik: 0001831828
- company_name: Vera Therapeutics, Inc.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831828/000119312523018203/0001193125-23-018203-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831828/000119312523018203/d381437d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-018203
- JSON: https://secwatch.observer/filing/0001193125-23-018203.json
- Plain text: https://secwatch.observer/filing/0001193125-23-018203.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.